Company:  CTI BIOPHARMA CORP (CTIC)
Form Type:  10-K
Filing Date:  3/31/1997 
CIK:  0000891293 
Address:  3101 WESTERN AVENUE
SUITE 600
 
City, State, Zip:  SEATTLE, Washington 98121 
Telephone:  (206) 282-7100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.45  
Change: 
0.06 (2.51%)  
Trade Time: 
01:27 PM EST  
Market Cap: 
$367.87M
Description of Business
We are a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. We are primarily focused on commercializing PIXUVRI�(pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe.
Register for a Free Trial and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA
        BALANCE SHEET
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        RESULTS OF OPERATIONS
        LIQUIDITY AND CAPITAL RESOURCES
      ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS
        REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      ITEM 9. CHANGES IN DISAGREEMENTS WITH ACCOUNTANTS ON ...
    PART III
      ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
        NAME AND TITLE
      ITEM 11. EXECUTIVE COMPENSATION
        COMPENSATION TABLE
        OPTIONS
        OPTIONS AGGREGATE
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
        BENEFICIAL OWNERS
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
    PART IV
      ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ...
        Report of Ernst & Young LLP, Independent Auditors
    SIGNATURES
  EXHIBIT 11.1
    COMPUTATION OF NET LOSS AND PRO FORMA NET LOSS PER SHARE
  EXHIBIT 22.1
  EXHIBIT 27